Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-Duchenne: CAP-1002 in DMD Cardiomyopathy
NCT02485938Phase 2Completed
- Sponsor
- Capricor Therapeutics
- Start
- Jan 2016
- Primary completion
- Sep 2017
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of deramiocel in Duchenne muscular dystrophy (DMD) and cardiomyopathy (2 arms), sponsored by Capricor Therapeutics. Primary endpoints: Number of Participants Experiencing Any of the Adjudicated Events, Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 12 months and 4 more. Started Jan 2016; status: completed.
02
Drugs
deramiocel
03
Conditions
Duchenne muscular dystrophy (DMD)cardiomyopathy
Beyond the preview
Go deeper on NCT02485938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485938.